Dexamethasone implant for immunogammopathy maculopathy associated with IgA multiple myeloma
- PMID: 30671569
- PMCID: PMC6329023
- DOI: 10.1177/2515841418820441
Dexamethasone implant for immunogammopathy maculopathy associated with IgA multiple myeloma
Abstract
Background: We describe a case where hyperviscosity retinopathy and immunogammopathy maculopathy were the presenting features of IgA multiple myeloma and report the response of maculopathy to intravitreal injection of dexamethasone implants.
Case presentation: A 56-year-old man presented at the Department of Ophthalmology with the chief complain of reduced vision for the past 10 days in both eyes. Ophthalmic examination revealed central retinal vein occlusion resembling signs with severe macular edema in both eyes with prominent serous macular detachment. After comprehensive evaluation, an IgA type kappa multiple myeloma was diagnosed complicated with hyperviscosity-associated retinopathy and immunogammopathy maculopathy. Patient was treated with multiple sessions of plasmapheresis, systemic chemotherapy, and finally intravitreal implants of dexamethasone with complete restoration of macular edema and serous macular detachment in both eyes. The visual function and the hyperviscosity-associated retinopathy were partially restored.
Conclusion: Ocular manifestation might be the only presenting sign of a life-threatening disease such as IgA multiple myeloma. A high level of suspicion is required to diagnose and treat such cases promptly and effectively.
Keywords: IgA multiple myeloma; chemotherapy; dexamethasone implants; hyperviscosity syndrome; hyperviscosity syndrome–associated retinopathy; immunogammopathy maculopathy; plasmapheresis.
Conflict of interest statement
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures



Similar articles
-
Hyperviscosity Retinopathy and Immunogammopathy Maculopahy as New Onset of Multiple Myeloma.Case Rep Ophthalmol. 2021 Jul 1;12(2):578-584. doi: 10.1159/000514695. eCollection 2021 May-Aug. Case Rep Ophthalmol. 2021. PMID: 34326757 Free PMC article.
-
Immunogammopathy maculopathy associated with Waldenström macroglobulinemia is refractory to conventional interventions for macular edema.Retin Cases Brief Rep. 2013 Fall;7(4):319-24. doi: 10.1097/ICB.0b013e31828ef0dc. Retin Cases Brief Rep. 2013. PMID: 25383828
-
Immunogammopathy Maculopathy Secondary to Waldenström's Macroglobulinemia Complicated With Diabetic Retinopathy: A Case Report and Literature Review.Cureus. 2023 Jul 10;15(7):e41622. doi: 10.7759/cureus.41622. eCollection 2023 Jul. Cureus. 2023. PMID: 37565119 Free PMC article.
-
Widening use of dexamethasone implant for the treatment of macular edema.Drug Des Devel Ther. 2017 Aug 16;11:2359-2372. doi: 10.2147/DDDT.S138922. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28860707 Free PMC article. Review.
-
Intravitreal dexamethasone implant therapy for the treatment of cystoid macular Oedema due to hydroxychloroquine retinopathy: a case report and literature review.BMC Ophthalmol. 2018 Dec 6;18(1):310. doi: 10.1186/s12886-018-0985-x. BMC Ophthalmol. 2018. PMID: 30522457 Free PMC article. Review.
Cited by
-
Cystoid macular oedema without leakage in fluorescein angiography: a literature review.Eye (Lond). 2023 Jun;37(8):1519-1526. doi: 10.1038/s41433-022-02230-z. Epub 2022 Sep 10. Eye (Lond). 2023. PMID: 36088420 Free PMC article. Review.
-
Atypical Refractory Macular Edema: Are We Missing Something?J Ophthalmic Vis Res. 2022 Aug 15;17(3):437-442. doi: 10.18502/jovr.v17i3.11584. eCollection 2022 Jul-Sep. J Ophthalmic Vis Res. 2022. PMID: 36160091 Free PMC article.
-
Multiple Myeloma Presenting as Recalcitrant Macular Edema.J Vitreoretin Dis. 2019 Oct 21;4(3):248-252. doi: 10.1177/2474126419880491. eCollection 2020 Jun. J Vitreoretin Dis. 2019. PMID: 37007440 Free PMC article.
-
Intravitreal Dexamethasone Implant as a Sustained Release Drug Delivery Device for the Treatment of Ocular Diseases: A Comprehensive Review of the Literature.Pharmaceutics. 2020 Jul 26;12(8):703. doi: 10.3390/pharmaceutics12080703. Pharmaceutics. 2020. PMID: 32722556 Free PMC article. Review.
-
Hyperviscosity Retinopathy and Immunogammopathy Maculopahy as New Onset of Multiple Myeloma.Case Rep Ophthalmol. 2021 Jul 1;12(2):578-584. doi: 10.1159/000514695. eCollection 2021 May-Aug. Case Rep Ophthalmol. 2021. PMID: 34326757 Free PMC article.
References
-
- Ziaei M, Elgohary MA, Bremner FD. Bilateral central retinal vein occlusion in multiple myeloma. Can J Ophthalmol 2013; 48: e24–e15. - PubMed
-
- Kwaan HC. Hyperviscosity in plasma cell dyscrasias. Clin Hemorheol Microcirc 2013; 55: 75–83. - PubMed
-
- Orellana J, Friedman AH. Ocular manifestations of multiple myeloma, Waldenström’s macroglobulinemia and benign monoclonal gammopathy. Surv Ophthalmol 1981; 26: 157–169. - PubMed
-
- Golesic EA, Sheidow TG. An otherwise healthy young man presents with bilateral CRVO as the first sign of hyperviscosity syndrome in the setting of new multiple myeloma. Retin Cases Brief Rep 2015; 9: 38–40. - PubMed
-
- Tuddenham EG, Whittaker JA, Bradley J, et al. Hyperviscosity syndrome in IgA multiple myeloma. Br J Haematol 1974; 27: 65–76. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous